Endothelial cell-targeted pVEGF165 polyplex plays a pivotal role in inhibiting intimal thickening after vascular injury

Abstract

Upregulation of vascular endothelial growth factor (VEGF) expression can inhibit intimal thickening after vascular injury. However, the lack of efficient gene delivery systems leads to insufficient VEGF expression, which prevents its application in gene therapy. In the present study, to improve the delivery of the plasmid vector with the VEGF gene (pVEGF165) to the injured vessel wall, we explored the potentially important difference between endothelial cell-targeted and nontargeted polymeric carriers. The α v β 3 integrin is overexpressed on activated endothelial cells but not on normal quiescent vessels. In this study, CDG2-cRGD, synthesized by conjugating an α v β 3 integrin-binding cyclic arginylglycylaspartic acid (cRGD) peptide with the Generation 2 polycation polyamidoamine (PAMAMG2)-g-cyclodextrin (termed as CDG2), was developed as a targetable carrier. It was observed that the specific integrin–ligand interactions greatly enhanced cellular internalization of CDG2-cRGD in human umbilical vein endothelial cells (HUVECs), which are notoriously difficult to transfect. Consequently, HUVECs were found to show remarkably high levels of VEGF165 expression induced by the CDG2-cRGD polyplex. Interestingly, VEGF165 overexpression in vivo was more complex than that in vitro, and in vivo assays demonstrated that the stimulus response to balloon injury in arteries could obviously upregulate VEGF165 expression in the saline-treated group, although it was not enough to prevent intimal thickening. In gene-transfected groups, intravascular delivery of pVEGF165 with the CDG2-cRGD polyplex into rabbits after vascular injury resulted in a significant inhibition of intimal thickening at 4 weeks, whereas the low therapeutic efficacy in the nontargeted CDG2-treated group was only comparable to that in the saline-treated group. It is becoming clear that the conflicting results of VEGF165 gene therapy in two gene-transfected groups are reflective of the pivotal role of the cRGD-conjugated carriers in achieving the beneficial therapeutic effects of vascular gene therapy.

Melatonin attenuates smoking-induced atherosclerosis by activating the Nrf2 pathway via NLRP3 inflammasomes in endothelial cells

“…VEGF plays an important role in mediating angiogenesis and endothelial cell tube formation. VEGF is capable of stimulating the proliferation of endothelial cells at injured sites, thereby precluding excessive vascular smooth muscle cell proliferation and consequent intimal thickening and stenosis [ 41 ]. eNOS, mainly expressed by vascular endothelium, is a key enzyme in producing nitric oxide, which can regulate vascular tone as well as endothelial permeability [ 42 ].…”

Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells

“…Delivery of plasmid encoding VEGF to vascular endothelial cells in a model of carotid artery injury enhanced recovery and inhibited neointimal hyperplasia [ 80 ]. Similarly, VEGF plasmid delivery to the endothelium in a rabbit model of balloon angioplasty-induced injury attenuated intimal thickening [ 81 ]. Delivery of eNOS plasmid directly to iliac artery endothelial cells via a stent promoted re-endothelialization and mitigated neointimal hyperplasia in a rabbit model of restenosis [ 82 ].…”

Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for Therapeutic Use in Age-Related Macular Degeneration Disease

“…Confocal laser scanning microscopy (CLSM) was used to observe the drug distribution in ARPE-19 cells and 293T cells after internalization of nanoparticles. Compared with the overexpression of integrin α v β 3 in ARPE-19 cells, the surface of 293T cells had an extremely low expression of integrin α v β 3 [35]. We used double fluorescent labeled nanoparticles to investigate the degree of cell internalization of nanoparticles.…”